Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Asthma COPD overlap syndrome

  • Slide deck and manuscript in Asthma COPD Overlap Syndrome (ACOS)
  • Structured literature review on ACOS
  • Adequacy of COPD PROs for patients with ACOS

Atopic keratoconjunctivitis

  • Evaluation of focus groups, item generation, cognitive debriefing and analysis plan in atopic keratoconjunctivitis
  • Poster communication on atopic keratoconjunctivitis
  • Manuscript in atopic keratoconjunctivitis

Atrial fibrillation

  • Analysis of atrial fibrillation in the UK
  • Qualitative research on PROs in atrial fibrillation
  • Development of PRO instrument modules and validation research in atrial fibrillation
  • Manuscript on the development of a symptoms questionnaire in atrial fibrillation
  • Decentralised framework for real life data generation in stroke prevention in atrial fibrillation (SPAF)
  • Reporting of development work in atrial fibrillation
  • Indirect comparison of two drugs used in the prevention of thromboembolic events due to atrial fibrillation
  • Analysis of the Anti-Clot Treatment Scale (ACTS), Treatment Satisfaction Questionnaire for Medication (TSQM) and healthcare resource utilization in a clinical trial in atrial fibrillation
  • Manuscript development on the ACTS/TSQM data
  • Manuscript support for statistical results in an observational study measuring outcomes in atrial fibrillation
  • Measurement of resource use, satisfaction, productivity and HRQoL in atrial fibrillation
  • Translation and validation of the ACTS and TSQM in atrial fibrillation in Japan


  • Equivalency testing of an eCOA version of the Vineland Adaptive Behavior Scales II (VABS-II) for use in autism spectrum disorder

Barth syndrome

  • Concept elicitation interviews in Barth syndrome patients
  • Concept selection meeting for a PRO in Barth syndrome
  • Cognitive debriefing for Barth syndrome PROs
  • Qualitative concept elicitation and case studies documenting the disease progression of Barth Syndrome



  • Payer value slide deck for a biosimilar in diabetes
  • Budget impact models for a biosimilar in type 1 and type 2 diabetes mellitus
  • Global value dossier, AMCP and accompanying slide sets for an insulin biosimilar


  • Payer value slides for immunology biosimilars
  • Frequently asked questions to support the introduction of a new biosimilar in immunology
  • Frequently asked questions for biosimilar policy in immunology
  • Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
  • Budget impact model for a biosimilar
  • Literature review and update to budget impact model in an immunology biosimilar
  • Updates to a US budget impact model for an immunology biosimilar
  • Update to an AMCP dossier for an immunology biosimilar
  • Originator vs. biosimilar value proposition update in immunology
  • Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar

Musculoskeletal diseases

  • Value message testing for a biosimilar in rheumatoid arthritis
  • Budget impact model for a biosimilar in autoimmune disease


  • Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
  • Development of a cost-calculator for a biosimilar for breast and gastric cancer
  • One-pager communication in a breast cancer biosimilar
  • Payer value deck update for a breast cancer biosimilar
  • Response to payer questions update for a breast cancer biosimilar
  • Budget impact model for a biosimilar in HER2 breast cancer

Women’s health

  • Development of a value dossier, health economic model and literature review in an infertility biosimilar to support pricing and reimbursement submissions in 15 EU countries
  • Pricing updates in Europe for a biosimilar hormone treatment for female infertility


  • Global value and reimbursement dossier for a biosimilar in autoimmune disease
  • Biosimilar payer communications in dermatology, gastroenterology and immunology
  • Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease (IBD), osteoarthritis, psoriasis and rheumatoid arthritis
  • Manuscript on a budget impact model for a biosimilar in haematology and rheumatology

Bipolar disorder

  • Systematic literature review and manuscript on the burden of illness in bipolar disorder
  • Psychometric validation of the Sheehan Disability Scale in bipolar disorder
  • Support network study to improve compliance in a psychotropic medication used in bipolar disorder
  • FDA PRO dossier on bipolar depression
  • Development of an endpoint model, training and recommendations for endpoint support in bipolar disorder
  • Composition of a PASS report on bipolar disorder, including a review of local physician monitoring guidelines
  • Validation of the Caregiver Strain Questionnaire in paediatric bipolar disease

Bladder cancer

  • Burden of disease deck in bladder cancer
  • Payer value deck in bladder cancer
  • Frequently asked questions in bladder cancer
  • Payer implementation guide in bladder cancer
  • Burden of disease deck, payer value dossier deck and frequently asked questions deck in 2nd line bladder cancer
  • Burden of disease deck in non-muscle invasive bladder cancer
  • Payer value deck update in 2nd line bladder cancer
  • Standardization of economic models in bladder cancer
  • Qualitative research in bladder cancer
  • Clinical trial analyses to support health-related quality of life in bladder cancer
  • ‘Fit for purpose’ tools review in bladder cancer
  • Development of a new PRO measure in bladder cancer
  • AMNOG analyses to support health-related quality of life in bladder cancer

Brain metastases

  • Development and validation of a PRO measure in brain metastases
  • Development and validation of a questionnaire to assess brain metastases
  • Linguistic validation of a brain metastases assessment